This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeAbout AboutWhy PENBRAYA?Risks of Meningococcal DiseaseGaps in Vaccination CoverageDosing & Recommendations Effectiveness & Safety Effectiveness
& Safety ImmunogenicitySafety ProfileIn Your Practice In Your PracticeSimplified CombinationHow to Transition to PENBRAYAPreparing PENBRAYAResources ResourcesRequest a RepresentativeHealth Plan CoverageMaterialsVideos
Prescribing InformationIndicationsPatient SiteRequest a RepLoading
PENBRAYA® is the first pentavalent (5-in-1) MenABCWY vaccine1-3Now you can offer broad protection against the 5 leading meningococcal serogroups (A, B, C, W, and Y) with one less injection1,2,4-10*†Now you can offer the broadest protection against the 5 leading meningococcal serogroups (A, B, C, W, and Y) with the fewest injections1-4*Icon of a shield and PENBRAYA (Meningococcal Groups A,B,C,W, and Y Vaccine) logo

Combination vaccine

PENBRAYA combines MenACWY coverage and Trumenba (Meningococcal Group B Vaccine) in a single vaccine product2‡

Icon with the letters A,B,C,W, and Y, representing the five leading types of meningococcal disease

Robust immunogenicity

PENBRAYA demonstrated robust immunogenicity against the 5 most common disease-causing meningococcal serogroups (A, B, C, W, and Y)2,4-9†

Icon of two syringes

Simplified combination

PENBRAYA, as a combination vaccine, may help simplify the meningococcal vaccination schedule and improve vaccine series completion rates1,2,11-13

Icon of a shield and plus sign

Broad coverage

PENBRAYA covers the majority of serogrouped meningococcal disease cases in a single vaccine product2,4-9†§

Vaccinate your healthy 
16-year-old patients with
5-in-1 PENBRAYA1,2

Vaccinate your healthy 
16-year-old patients with 5-in-1 PENBRAYA1,2

One less injection is needed for healthy adolescents at age 16 to complete the recommended meningococcal vaccination schedule compared to separate MenACWY and MenB vaccines.1Based on data in the CDC-enhanced meningococcal surveillance reports from 2017 to 2022 for 16- to 23-year-olds. The number of cases for each serogroup were as follows: MenA=0; MenB=120; MenC=20; MenW=5; MenY=9; other/unknown=31; and non-groupable=49.4-9PENBRAYA was studied and approved as part of a 2-dose series to help prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y.2,14PENBRAYA will not protect 100% of vaccinated individuals.2,14CDC=Centers for Disease Control and Prevention.Quick links

Order, track, and pay for PENBRAYA with Pfizer Prime

 Order  nowLoadingIcon of an information speech bubble

Meningococcal Disease Risks

Understand why fully vaccinating your adolescent patients is critical

 See disease risks LoadingIcon of a syringe

Gaps in Coverage

Disparities in meningococcal vaccination among adolescents contribute to gaps in coverage∥

 Discover more LoadingAmong adolescents and young adults, those 16 through 23 years old have the highest rates of meningococcal disease.15circle icon of a speech bubble representing meningococcal disease risks

Meningococcal Disease Risks

Understand why fully vaccinating your adolescent patients is critical

 See disease risks Loadingcircle icon of a syringe representing gaps in coverage

Gaps in Coverage

Disparities in meningococcal vaccination among adolescents contribute to gaps in coverage∥

 Discover more LoadingAmong adolescents and young adults, those 16 through 23 years old have the highest rates of meningococcal disease.15References: 1. Collins JP, Crowe SJ, Ortega-Sanchez IR, et al. Use of the Pfizer pentavalent meningococcal vaccine among persons aged ≥10 years: recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73(15):345-350. 2. PENBRAYA® (Meningococcal Groups A, B, C, W, and Y Vaccine). Prescribing information. Pfizer Inc.; 2024. 3. Centers for Disease Control and Prevention. Meningococcal disease: meningococcal vaccination. Updated June 26, 2024. Accessed January 13, 2025. https://www.cdc.gov/meningococcal/vaccines/index.html 4. Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2017: confirmed and probable cases reported to the National Notifiable Diseases Surveillance System, 2017. Published October 7, 2019. Accessed February 3, 2025. https://stacks.cdc.gov/view/cdc/140464 5. Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2018: confirmed and probable cases reported to the National Notifiable Diseases Surveillance System, 2018. Published October 7, 2019. Accessed February 3, 2025. https://stacks.cdc.gov/view/cdc/111348 6. Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2019: confirmed and probable cases reported to the National Notifiable Diseases Surveillance System, 2019. Updated May 11, 2023. Accessed February 3, 2025. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2019.pdf 7. Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2020: confirmed and probable cases reported to the National Notifiable Diseases Surveillance System, 2020. Updated May 11, 2023. Accessed February 3, 2025. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2020.pdf 8. Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2021: confirmed and probable cases reported to the National Notifiable Diseases Surveillance System, 2021. Updated June 21, 2023. Accessed February 3, 2025. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2021.pdf 9. Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2022: confirmed and probable cases reported to the National Notifiable Diseases Surveillance System, 2022. Updated April 8, 2024. Accessed February 3, 2025. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2022-508.pdf 10. Pingali C, Yankey D, Chen M, et al. National vaccination coverage among adolescents aged 13-17 years—National Immunization Survey–Teen, United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73(33):708-714. 11. Bekkat-Berkani R, Fragapane E, Preiss S, et al. Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB. J Infect. 2022;85(5):481-491. 12. Kroger A, Bahta L, Long S, Sanchez P. General best practice guidelines for immunization. Centers for Disease Control and Prevention. Accessed January 13, 2025. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf 13. Esposito S, Principi N, Cornaglia G; for the ESCMID Vaccine Study Group (EVASG). Barriers to the vaccination of children and adolescents and possible solutions. Clin Microbiol Infect. 2014;20(suppl 5):25-31. 14. FDA approves PENBRAYATM, the first and only vaccine for the prevention of the five most common serogroups causing meningococcal disease in adolescents. Press release. Pfizer Inc.; October 20, 2023. 15. Centers for Disease Control and Prevention. Meningococcal disease surveillance and trends. Last reviewed November 12, 2024. Accessed January 13, 2025. https://www.cdc.gov/meningococcal/php/surveillance/index.html

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PBI-USA-0409
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-MCL-USA-0367
Indications
  • PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age
  • TRUMENBA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. TRUMENBA is approved for use in individuals 10 through 25 years of age 
Important Safety Information
  • Do not administer PENBRAYA or TRUMENBA to individuals with a history of severe allergic reaction (eg, anaphylaxis) to any component of PENBRAYA or TRUMENBA. Appropriate medical treatment used to manage allergic reactions must be available in the event an anaphylactic reaction occurs immediately following administration of PENBRAYA or TRUMENBA
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including PENBRAYA or TRUMENBA. Procedures should be in place to avoid injury from fainting
  • Some individuals with altered immunocompetence may have reduced immune responses to PENBRAYA or TRUMENBA
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by N. meningitidis groups A, B, C, W, and Y, even if they develop antibodies following vaccination with PENBRAYA
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by N. meningitidis group B, even if they develop antibodies following vaccination with TRUMENBA
  • Vaccination with PENBRAYA or TRUMENBA may not protect all vaccine recipients
  • Vaccination with PENBRAYA does not substitute for vaccination with a tetanus toxoid–containing vaccine to prevent tetanus
  • Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision by the healthcare professional to administer PENBRAYA to individuals with a history of GBS should take into account the expected benefits and potential risks 
  • For PENBRAYA, the most commonly reported (≥15%) solicited adverse reactions after Dose 1 and Dose 2, respectively, were pain at the injection site (89% and 84%), fatigue (52% and 48%), headache (47% and 40%), muscle pain (26% and 23%), injection site redness (26% and 23%), injection site swelling (25% and 24%), joint pain (20% and 18%), and chills (20% and 16%)
  • For TRUMENBA, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%)
  • Data are not available on the safety and effectiveness of using TRUMENBA and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • The safety and effectiveness of PENBRAYA or TRUMENBA have not been established in pregnant individuals
     
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for PENBRAYA and full Prescribing Information for TRUMENBA.Indications
  • PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age
  • TRUMENBA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. TRUMENBA is approved for use in individuals 10 through 25 years of age